Biopharmaceutical firm AbbVie has received breakthrough therapy status from the US Food and Drug Administration (FDA) for its venetoclax in combination with rituximab to treat patients with relapsed / refractory chronic lymphocytic leukemia (R/R CLL).

Venetoclax is an inhibitor of the B-cell lymphoma-2 (BCL-2) protein, which is being developed by AbbVie in collaboration with Genentech and Roche.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The FDA has provided the designation based on the results of an investigational study of venetoclax in combination with rituximab in patients with R/R CLL.

Rituximab is indicated in combination with fludarabine and cyclophosphamide to treat patients with previously untreated and previously treated CD20-positive CLL.

"AbbVie will continue harnessing our collective expertise to accelerate efforts for bringing new treatment options to patients battling this difficult-to-treat blood cancer."

According to the company, Rituximab in combination with the investigational agent venetoclax has not yet received approval for the treatment of R/R CLL.

AbbVie research and development executive vice president and chief scientific officer Dr Michael Severino said: "This second breakthrough therapy designation for venetoclax granted by the FDA underscores the significant potential of this therapy in treating relapsed / refractory CLL patients, and reflects AbbVie’s commitment to providing breakthrough therapies for cancer patients.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

"AbbVie will continue harnessing our collective expertise to accelerate efforts for bringing new treatment options to patients battling this difficult-to-treat blood cancer."

Last April, the FDA granted breakthrough therapy status to single agent venetoclax for the treatment of CLL in previously treated (relapsed / refractory) patients with the 17p deletion genetic mutation.

Currently, Venetoclax is being assessed for the treatment of patients with various cancer types.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now